In rat models of ovarian cancer, DEX treatment could effectively decrease the plasma concentration of TNF-α and enhance the immunity through various signaling pathways, which eventually inhibited tumor growth, invasion, and migration [92,93]. This evidence concerns the gene TNF and ovarian carcinoma.